Literature DB >> 10068572

Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons.

J J Lefrère1, F Roudot-Thoraval, L Morand-Joubert, J C Petit, J Lerable, M Thauvin, M Mariotti.   

Abstract

The prevalence of GB virus C (GBV-C) infection is high in human immunodeficiency virus (HIV)-infected persons. However, the long-term consequences of coinfection are unknown. HIV-positive persons with a well-defined duration of infection were screened on the basis of their GBV-C/hepatitis G virus (HGV) RNA status and studied. GBV-C/HGV viremia was observed in 23, who carried the virus over a mean of 7.7 years. All parameters (survival, CDC stage B/C, HIV RNA load, CD4 T cell count) showed significant differences in terms of the cumulative progression rate between persons positive and negative for GBV-C/HGV RNA. When GBV-C/HGV RNA-positive and -unexposed subjects were matched by age, sex, baseline HIV RNA load, and baseline CD4 T cell count, HIV disease progression appeared worse in GBV-C/HGV RNA-negative subjects. The carriage of GBV-C/HGV RNA is associated with a slower progression of HIV disease in coinfected persons.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10068572     DOI: 10.1086/314671

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

1.  Human Pegivirus infection and lymphoma risk and prognosis: a North American study.

Authors:  Angelo Fama; Jinhua Xiang; Brian K Link; Cristine Allmer; Donna Klinzman; Andrew L Feldman; Grzegorz S Nowakowski; Mark Liebow; Melissa C Larson; Matthew J Maurer; Stephen M Ansell; Anne J Novak; Yan W Asmann; Susan L Slager; Timothy G Call; Thomas M Habermann; James R Cerhan; Jack T Stapleton
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998

2.  Prevalence and genotypic variability of TTV in HIV-infected patients.

Authors:  K E Sherman; S D Rouster; J Feinberg
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

Review 3.  GBV-C: state of the art and future prospects.

Authors:  Maria Teresa Maidana Giret; Esper Georges Kallas
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

4.  Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication.

Authors:  Jinhua Xiang; James H McLinden; Thomas M Kaufman; Emma L Mohr; Nirjal Bhattarai; Qing Chang; Jack T Stapleton
Journal:  Virology       Date:  2012-05-16       Impact factor: 3.616

Review 5.  Role of GB virus C in modulating HIV disease.

Authors:  Carolynne Schwarze-Zander; Jason T Blackard; Juergen K Rockstroh
Journal:  Expert Rev Anti Infect Ther       Date:  2012-05       Impact factor: 5.091

6.  GB virus C infection among young, HIV-negative injection drug users with and without hepatitis C virus infection.

Authors:  B Boodram; R C Hershow; D Klinzman; J T Stapleton
Journal:  J Viral Hepat       Date:  2011-04       Impact factor: 3.728

Review 7.  Effect of treating co-infections on HIV-1 viral load: a systematic review.

Authors:  Kayvon Modjarrad; Sten H Vermund
Journal:  Lancet Infect Dis       Date:  2010-07       Impact factor: 25.071

8.  Cytokine/chemokine expression associated with Human Pegivirus (HPgV) infection in women with HIV.

Authors:  Jason T Blackard; Gang Ma; Jeffrey A Welge; Lynn E Taylor; Kenneth H Mayer; Robert S Klein; David D Celentano; Jack D Sobel; Denise J Jamieson; Caroline C King
Journal:  J Med Virol       Date:  2017-08-28       Impact factor: 2.327

9.  Effect of primer selection on estimates of GB virus C (GBV-C) prevalence and response to antiretroviral therapy for optimal testing for GBV-C viremia.

Authors:  I E Souza; J B Allen; J Xiang; D Klinzman; R Diaz; S Zhang; K Chaloner; D Zdunek; G Hess; C F Williams; L Benning; J T Stapleton
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

10.  Human pegivirus (HPgV) infection in Ghanaians co-infected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

Authors:  Kombo F N'Guessan; Ceejay Boyce; Awewura Kwara; Timothy N A Archampong; Margaret Lartey; Kwamena W Sagoe; Ernest Kenu; Adjoa Obo-Akwa; Jason T Blackard
Journal:  Virus Genes       Date:  2018-03-17       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.